undamentalytics Newsletter
Sign in

Cumberland Pharmaceuticals Inc income statement

In fiscal 2025, Cumberland Pharmaceuticals Inc reported revenue of $44.5m, up 17.6% on the year before, operating income of −$2.8m (a -6.3% margin) and net income of −$2.8m, or −$0.19 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2009Dec 20092010Dec 20102011Dec 20112012Dec 20122013Dec 20132014Dec 20142015Dec 20152016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue444651493237343341293437364240384540
Cost of revenue———————6767999677—
Gross profit———————27342327292733333138—
Research and development545563434876676565
Selling and marketing2023212014151415211415151517181719—
General and administrative8899988910101010101011111212
Operating income67109−441−1−4−11−9−6−8−6−10−6−3−10
Interest expense110000000000011100
Income before tax55109−441−1−4−11−9−7−6−6−6−6−3−10
Income tax2343−211−040−00000−000
Net income3266−221−1−8−7−4−3−4−6−6−6−3−11
Diluted EPS$0.17$0.12$0.28$0.30−$0.11$0.14$0.04−$0.06−$0.50−$0.45−$0.23−$0.22−$0.24−$0.38−$0.44−$0.46−$0.19−$0.74
Diluted shares (average)18m21m21m20m18m18m17m16m16m16m15m15m15m15m14m14m15m15m
EBITDA771110−2631−1−8−5−2−3−0−5−21−5

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: CPIX vs IMCCBGM vs CPIXCPIX vs SBFMBFRI vs CPIX

More: Pharmaceuticals stocks compared, Health Care sector, rankings of US companies

Figures from Cumberland Pharmaceuticals Inc's SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Cumberland Pharmaceuticals Inc.